Treatment of Pulmonary Langerhans Cell Histiocytosis with Multisystem Disease in Children Under 18
Clinical Scenario
This protocol covers Langerhans cell histiocytosis in children and adolescents under 18 years of age who present with systemic disease — either involvement of two or more organs or organ systems (multisystem LCH), or disease affecting two or more anatomically separate bones (multifocal bone disease).
The patient in this scenario has no risk organ involvement at diagnosis: the hematopoietic system, liver, and spleen are clear. This places the patient in the low-risk stratum, associated with a probability of survival of nearly 100%.
Key Conditions
- Age: under 18 years
- Disease extent: two or more organs/systems, or two or more anatomically separate bone lesions
- Risk organ status: none involved (no hematopoietic, hepatic, or splenic involvement)
Treatment Approach
Front-line management in this setting involves a combination of two therapeutic classes — a corticosteroid and a chemotherapy agent — given in a structured initial phase followed by a continuation phase. The full protocol specifies the agents, administration schedule, and total treatment duration; access it below.
Treatment Goals
The primary objective is non-active disease (complete resolution) or meaningful regression (AD-better). Response is formally assessed at the completion of the initial therapy phase — at week 7 or week 13 — and again at the end of continuation therapy.
References
- This document refers to Langerhans cell histiocytosis with onset in childhood and adolescence (age < 18 years).
- Multisystem LCH and multifocal skeletal disease indicate systemic treatment.
- Involvement of two or more anatomically separate bones is categorized as "multifocal bone disease".
- Risk organ involvement at diagnosis (defined as at least one of the following: peripheral blood cytopenia and/or liver enlargement ± organ dysfunction and/or spleen enlargement) allows stratification of MS-LCH into low risk (probability of survival of nearly 100%) and risk group (probability of survival of 80-90%).
- The combination of prednisolone plus vinblastine is the most extensively studied first-line therapy in pediatric-onset LCH.
- It consists of 6–12 weeks of initial therapy (oral steroids and weekly vinblastine injections), followed by a continuation therapy given to total treatment duration of 12 months.
- The continuation therapy consists of prednisolone (day 1–5) / vinblastine (day 1) pulses given every 3 weeks.
- Assessment of disease activity, and respectively of response to treatment, are recommended upon completion of initial (week 7 or 13) and of continuation therapy.
View source ↗